Crude SlrP‐Conjugated Mesoporous Silica Nanoparticles: Promising Anticancer Therapeutics

Abstract The study presents a novel nanocarrier technology that integrates mesoporous silica nanoparticles (MSNs) with the bacterial effector protein SlrP for targeted cancer treatment. It is proposed that the conjugation of SlrP to carboxyl‐functionalized, fluorescein‐labeled mesoporous silica nanoparticles (MSN FITC/MPA ) will facilitate regulated intracellular distribution and enhance cytotoxic effects in colorectal cancer cells. This method distinctively combines the apoptosis‐inducing protein SlrP with a biocompatible, traceable MSN platform, in contrast to conventional delivery techniques. Thorough characterization validated the effective synthesis, carboxylation, and SlrP conjugation, preserving particle integrity and improving surface functionality. Cellular investigations utilizing Caco‐2 cells revealed effective absorption, delayed release, and markedly elevated cytotoxicity and apoptosis rates in comparison to free SlrP. Significantly, MSN FITC/MPA/SlrP conjugates prompted G 0 /G 1 phase arrest and a time‐dependent development of apoptosis, highlighting the therapeutic potential of the system. This study presents a novel protein‐nanoparticle hybrid that overcomes challenges in protein drug delivery and emphasizes mesoporous silica nanoparticles as a viable platform for targeted sustained cancer therapy.